TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8172139
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment or placebo)
Study: 30522806
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 0.5–0.6 × 10^8 allogenic placenta-derived MSCs
Study: 26353784
Drug: Truce program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Truce program (7-week acceptance and commitment therapy)
Study: 19142978
Drug: Prelox (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prelox (combination of l-arginine aspartate and Pycnogenol)
Study: 17519075
Drug: IL‐12/23 mAb
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐12/23 mAb (0.27, 0.675, 1.35, and 2.7 mg/kg)
Study: 10606880
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH), 250 U/kg twice daily
Study: 10606880
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH), 300 U/kg once daily
Study: 10606880
Drug: Dalteparin, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin, 200 U/kg once daily
Study: 10606880
Drug: Enoxaparin, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin, 1.5 mg/kg once daily
Study: 7750288
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of vitamin C (gram quantities)
Study: 7750288
Drug: Combination oral
Normalized name: PROBIOTIC COMBINATION ORAL CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination oral contraceptive alone
Study: 2292897
Drug: Teolin 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teolin 300 tablets (TT)
Study: 2292897
Drug: Teotard 350
Normalized name: Ketotard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teotard 350 capsules (TC)
Study: 7016451
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg tolmetin sodium daily
Study: 1092728
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg naproxen daily
Study: 25517106
Drug: 7.5% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% sucrose drink containing 6 g of l-citrulline
Study: 25517106
Drug: 710 mL
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 710 mL of watermelon juice (1.0 g citrulline)
Study: 21679291
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (single pre-prandial dose)
Study: 21679291
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (basal-only control)
Study: 15012046
Drug: Exercise during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise during dialysis (cycling ergometer sessions, twice weekly for 12 sessions)
Study: 21813912
Drug: NO(2) Platinum
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO(2) Platinum (12 g/day)
Study: 19103500
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g bolus before skin incision and 400 mg/h during surgery)
Study: 9265991
Drug: Cetirizine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine treatment for allergic cough
Study: 3404638
Drug: Adjusted-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose heparin (mean 13,200 +/- 2200 U per dose, APTT 1 1/2 times control)
Study: 3404638
Drug: Fixed-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose heparin (5000 U subcutaneously twice daily)
Study: 30346496
Drug: Standard PIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PIL (e.g., 'Common, 1 in 10 people will be affected')
Study: 30346496
Drug: Positively framed
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positively framed PIL (e.g., 'Uncommon, 90% of people will not be affected')
Study: 12760589
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg 8 hourly for two weeks
Study: 10857950
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (AHT) with enalapril or metoprolol
Study: 10857950
Drug: No antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antihypertensive treatment (AHT)
Study: 2053757
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 1 or 2 g of oxacillin before surgery, followed by four days of oral oxacillin (3 g per day).
Study: 2053757
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without the use of prophylactic antibiotics.
Study: 7049344
Drug: Intrathecal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal therapy with methotrexate, hydrocortisone, and cytosine arabinoside plus cranial radiation (2400 rad over 2 1/2 weeks)
Study: 7049344
Drug: Intrathecal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal therapy with methotrexate, hydrocortisone, and cytosine arabinoside without cranial radiation
Study: 26469916
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without collection of wound exudate
Study: 21207054
Drug: CRE +
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CRE + CAF (0.3 g kg(‐1) day(‐1) of creatine for 5 days and followed by 6 mg kg(‐1) of caffeine)
Study: 21207054
Drug: CRE +
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CRE + PLA (0.3 g kg(‐1) day(‐1) of creatine for 5 days then followed by 6 mg kg(‐1) of placebo)
Study: 15467309
Drug: Desmopressin (DDAVP)
Normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin (DDAVP) at a dose of 2 microg/kg intranasally
Study: 11208820
Drug: Preoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiation with cisplatin, fluorouracil, and vinblastine; cisplatin 20 mg/m2/d on days 1-5 and 17-21, fluorouracil 300 mg/m2/d on days 1-21, vinblastine 1 mg/m2/d on days 1-4 and 17-20, radiotherapy 1.5-Gy fractions twice daily for 21 days to a total dose of 45 Gy.
Study: 3275909
Drug: ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinyl estradiol 35 micrograms plus ethynodiol diacetate 1 mg
Study: 3275909
Drug: ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinyl estradiol 30 micrograms plus levonorgestrel 0.15 mg
Study: 3275909
Drug: ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinyl estradiol 35 micrograms plus norethindrone 1 mg
Study: 3275909
Drug: ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinyl estradiol 35 micrograms plus norethindrone 0.5 and 1 mg (biphasic)
Study: 24711000
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 100mg/kg/day as intermittent intravenous infusion from day -6 to day +15
Study: 16995478
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus preoperative IL-2 administration (19 patients)
Study: 8636768
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (carmustine, etoposide, cytarabine, and cyclophosphamide [BEAC]) followed by autologous bone marrow transplantation (ABMT)
Study: 1619995
Drug: Naloxone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.8 mg bolus followed by 0.04 mg/kg/h infusion)
Study: 30955478
Drug: Educational text
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational text messages about osteoporosis (daily for one month)
Study: 19056011
Drug: Drotrecogin α
Normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotrecogin α (activated) treatment
Study: 7603811
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil suspension (20 mg/kg/day twice daily for 4 days)
Study: 7603811
Drug: Penicillin suspension
Normalized name: Penicillin V
DrugBank: Meticillin (DB01603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin suspension (45 mg/kg/day divided three times daily for 10 days)
Study: 28514299
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal patch
Study: 28514299
Drug: Parecoxib intravenous
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib intravenous injection (Group A)
Study: 28514299
Drug: Oral celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral celecoxib (Group B)
Study: 26573452
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (20 intermittent presses to the patella and olecranon)
Study: 18523893
Drug: Standardized advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized advice and a dose tapering schedule
Study: 14627859
Drug: 17beta-estradiol gel
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17beta-estradiol gel 2.5 g (1.5 mg estradiol)
Study: 14627859
Drug: 17beta-estradiol gel
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17beta-estradiol gel 1.25 g (0.75 mg estradiol)
Study: 14627859
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (17beta-estradiol gel 2.5 g, 17beta-estradiol gel 1.25 g, placebo)
Study: 11566168
Drug: 10‐mg atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg atorvastatin
Study: 8053744
Drug: Glutamine-supplemented TPN
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-supplemented TPN (0.18 g of glutamine/kg/d)
Study: 8053744
Drug: Conventional TPN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional TPN (0.2 g nitrogen/kg/d)
Study: 2965375
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (CY 222) at a fixed dose of 750 anti-Xa units
Study: 2965375
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin at a dose of 500 IU/kg/24 h
Study: 8345416
Drug: Somatotropin, 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatotropin, 0.3 mg/kg per week, administered subcutaneously three times weekly (n = 63)
Study: 8345416
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of somatotropin (n = 92)
Study: 8345416
Drug: Three-times-weekly dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-times-weekly dosing of somatotropin (n = 92)
Study: 76842
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclophosphamide, 5‐fluorouracil, and prednisone (C.F.P.) with or without radiotherapy
Study: 26666258
Drug: MEDI-551, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-551, a monoclonal antibody that depletes CD19+ B-cells
Study: 12021573
Drug: Tezosentan 100
Normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan 100 mg
Study: 12021573
Drug: Tezosentan 200
Normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan 200 mg
Study: 12021573
Drug: Tezosentan 400
Normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan 400 mg
Study: 12021573
Drug: Tezosentan 600
Normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan 600 mg
Study: 12021573
Drug: Tezosentan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan (all doses)
Study: 8007742
Drug: L-Thyroxin Henning
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Thyroxin Henning
Study: 8007742
Drug: Another tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Another tablet preparation
Study: 8007742
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of levothyroxine (reference solution)
Study: 2509007
Drug: Calcitonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin treatment (100 U by subcutaneous self-application on alternate days for 6-8 weeks)
Study: 2509007
Drug: Cyclical hormone
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical hormone replacement therapy (over 12 months)
Study: 2509007
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (analgetic treatment and 500 mg Ca daily)
Study: 1099526
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of ASA
Study: 1099526
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of lactose (placebo)
Study: 23553060
Drug: Heparin lock
Normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin lock (300 U/3 ml)
Study: 22212315
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus epidural of 2 mg/10 mL morphine
Study: 15385829
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of micronized 17beta‐estradiol valerate (E2V)
Study: 15385829
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of E2V in combination with 5 mg of medroxyprogesterone acetate (MPA)
Study: 9410554
Drug: Lispro insulin
Normalized name: Lispro insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lispro insulin analog
Study: 26862625
Drug: Fentanyl-bupivacaine-morphine
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl-bupivacaine-morphine
Study: 16645357
Drug: Valsartan (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (titrated up to 320 mg)
Study: 8912074
Drug: Early definitive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early definitive treatment with antrectomy or pyloroplasty
Study: 31137959
Drug: Weekly real-time
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly real-time adherence feedback via SMS using Wisepill device
Study: 19541792
Drug: Oral casopitant
Normalized name: maropitant Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral casopitant 50 mg
Study: 19541792
Drug: Oral casopitant
Normalized name: maropitant Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral casopitant 100 mg
Study: 19541792
Drug: Oral casopitant
Normalized name: maropitant Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral casopitant 150 mg
Study: 19541792
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral casopitant 150 mg
Study: 16510744
Drug: Natalizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab (300 mg, intravenous infusion every four weeks for more than two years)
Study: 16510744
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous infusion every four weeks for more than two years)
Study: 12752404
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) intravenous infusion
Study: 10956377
Drug: L-carnitine and
Normalized name: Fat Burner with Chromium Picolinate, L-Carnitine and Iron Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine and acetyl-L-carnitine
Study: 29968301
Drug: salbutamol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: salbutamol (6 × 4 mg oral)
Study: 21084036
Drug: rHuEPO plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO plus oral oxymetholone (50 mg/tablet twice daily)
Study: 18958840
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and pioglitazone combined treatment
Study: 18958840
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with atorvastatin and pioglitazone
Study: 30870770
Drug: Treatment As
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment As Usual (TAU; n = 11)
Study: 29161988
Drug: Obligatory daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obligatory daily school-based physical activity (5×45 minutes per week)
Study: 26886651
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading of 1.0 μg/kg for 20 minutes before the termination of surgery)
Study: 24576512
Drug: Faith-based therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faith-based therapeutic lifestyle change (TLC) intervention delivered through 11 weekly sessions and 3 monthly motivational interviewing sessions.
Study: 24576512
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education (HE) control delivered through 11 weekly classes on hypertension and other health topics.
Study: 23383460
Drug: Belt Vessel
Normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belt Vessel (Daimai) Regulation Acupoint Recipe with electroacupuncture applied to bilateral GB 26 and ST 25, treatment conducted once every other day for 8 weeks
Study: 15942734
Drug: PrepStart (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrepStart (combination of Prep and Start)
Study: 8815279
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus glucocorticoids
Study: 1737529
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (6 separate monthly injections)
Study: 1737529
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (6 insulin-dependent diabetic subjects treated with human insulin)
Study: 6385785
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dexamethasone
Study: 30137325
Drug: Ovarian stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian stimulation with Clomiphene Citrate (100 mg)
Study: 27974124
Drug: Low-dose gamma
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose gamma globulin (0.2 g/(kg · d)) combined with methylprednisolone
Study: 27974124
Drug: High-dose gamma
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose gamma globulin (0.4 g/(kg · d)) combined with methylprednisolone
Study: 25232263
Drug: Otilonium bromide
Normalized name: otilonium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilonium bromide 80 mg
Study: 25232263
Drug: Otilonium bromide
Normalized name: otilonium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilonium bromide 40 mg
Study: 7284220
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (6-8ml of 0.5% bupivacaine solution)
Study: 7284220
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (10-14ml of 0.25% bupivacaine solution)
Study: 7284220
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (6-8ml of 0.25% bupivacaine solution)
Study: 29949455
Drug: MABT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MABT + treatment as usual (TAU)
Study: 28590363
Drug: dl‐MPH (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl‐MPH (40 mg) with ethanol (0.6 g/kg)
Study: 28590363
Drug: d‐MPH (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH (20 mg) with ethanol (0.6 g/kg)
Study: 28590363
Drug: dl‐MPH (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl‐MPH (40 mg)
Study: 28590363
Drug: d‐MPH (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH (20 mg)
Study: 24809922
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) - aspirin and clopidogrel 75 mg/qd or ticlopidine 500 mg/bid
Study: 24809922
Drug: Single antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antiplatelet therapy (ASA) - aspirin only
Study: 22761759
Drug: 2 single
Normalized name: ACL2 SINGLE SHOT EPIDURAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 single doses (3.75 µg hemagglutinin)
Study: 22761759
Drug: 2 double
Normalized name: Flora-Q 2 Double Strength Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 double doses (7.5 µg hemagglutinin)
Study: 22761759
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose (control group)
Study: 20638380
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine (15 mg)
Study: 20638380
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine (30 mg)